Chat Room I Cyber Monday Extendedπ I Trade the SPY | | | Good day, 360 – | Jeff Bishop is hosting a special Lunch session π₯ͺ today to kick off the new month, so make sure you have RB MarketMasters access. This can be secured HERE or through one of the chat-based services including Market Navigator, Atomic Trades or Elite – all are on great monthly sales right now! | Be the best prepared trader on the Street! | | FOCUS LISTπ | NEXI - Trades up over 300% in pre-market on NO news | BIOR - Up over 40% in pre-market after receiving FDA clearance for Ulcerative Colitis treatment | ALT - Up over 35% in pre after positive Phase 2 obesity drug results | | SPOTLIGHTπ‘ | *sponsored by Motion | | | The problem: your team isn't shipping enough winning creative to scale ad accounts. | The solution: get your team to master the art and science of creative strategy with Thumbstop. | Every Sunday, you'll learn how to bridge the gap between media buying and creative, helping you ship more winning TikTok, Facebook, and YouTube ads. | You'll learn: | ⚡️ The Art: creativity cheat codes, trending ad formats backed by Motion data, and how to build creative performance teams the right way. | π¬ The Science: analytical skills that make marketers 10X more valuable, tales of scale & experimentation, and advanced creative analysis techniques. | Subscribe to Thumbstop |
|
| | HOTLISTπ₯ | NEXI - Trades up over 300% in pre-market on no news | NexImmune (NEXI) is a clinical-stage biotechnology company that engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. | NEXI has had no news in recent days, however it has seen increased trading volume. The small cap biotech sector has caught fire recently, with big moves in stocks like VVOS and MINM. According to Finviz, VVOS has a float of only 660k shares, and traders have come in force in the premarket pushing the stock higher. | | The $10 area has acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $12, $12.50, and then the pre-market high at $13.23. Beyond that, things can get even more wild as $18, $20 and even higher come into play. | Below $10, there is potential support at $9, $8, $6.50, $4.30, with a gap to fill at $2.48. | | BIOR - Up over 40% in pre-market after receiving FDA clearance for Ulcerative Colitis treatment | Biora Therapeutics (BIOR) is a biotechnology company that engages in developing oral biotherapeutics. | In the after-hours yesterday, the company announced that it had received FDA clearance of an IND application for Drug/Device combination BT-600 targeting the treatment of Ulcerative Colitis. | The phase 1 trial of BT-600 is planned as a randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate safety, pharmacokinetics and pharmacodynamics, including effects on colon tissue. | The stock was trading up over 40% in pre-market after the news. | | The $1.90 area acted as support in the pre-market and now becomes a potential resistance level. | Above it, targets to the upside are $2, $2.20 and then the pre-market high at $2.32. Beyond that, $2.50, $2.70, $3 and $3.30 come into play. | Below $1.90, there is potential support at $1.66, $1.50 and a gap to fill at $1.24. | | ALT - Up over 35% in pre after positive Phase 2 obesity drug results | Altimmune (ALT) is a clinical stage biopharmaceutical company that focuses on developing treatments for obesity and liver diseases. | In the after-hours yesterday ALT announced positive Phase 2 obesity results for its drug Pemvidutide. The company reported it had achieved mean weight loss of 15.6% on 2.4Mg does of Pemvidutide at week 48. Over 30% of subjects achieved 20% or more weight loss on 2.4 mg dose at 48 weeks Robust | The stock was trading up over 35% in pre-market on the news. | | The $4.20 area has acted as support so far in the pre-market. | Above it, targets to the upside are $4.60, $5 and then the pre-market high $5.25. Beyond that, $5.50, $6 and $6.94 come into play with a gap fill at $10.92. | Below $4.20, there is potential support at $4, $3.80, $3.60, $3.40 and a gap to fill at $3.16. | | POLL: Your vote matters! | VOTE! NVDA broke below a major support level yesterday | | | MARKET NEWS | | | π₯ More GREAT trading resources: | For great training in options basics, start your journey Jeff Williams | Get instant access to Jeff Bishop's top trading ideas | For great training in options basics, start your journey Jeff Williams. | | Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull | | DISCLAIMER To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer | *Sponsored content: We're a proud affiliate for Motion, meaning if you click a link for a product or service, we may earn a commission at no extra cost to you. We believe in the companies we form affiliate relationships with, but please don't spend any money on these products or services unless you believe they will help you achieve your goals. | FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. | RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. | RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. | RagingBull.com, LLC shall be entitled to recover attorneys' fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys' fees, costs and disbursements in addition to any other relief to which it may be entitled. | WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. |
|
| |
|
Tiada ulasan:
Catat Ulasan